PTC Therapeutics reported $82.88M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 540M 1000K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
Daiichi Sankyo JPY 1.82B 30.68M Jun/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026
Xencor USD 74.06M 2.19M Mar/2026